Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Shenzhen Geno-Immune Medical Institute

Country

Ownership: Private

Established: 2015-04-28

Employees: -

Market Cap: -

Website

Clinical Trials

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Phase 1

Conditions: T-cell Acute Lymphoblastic Lymphoma
Acute Myeloid Leukemia
T-cell Acute Lymphoblastic Leukemia
NK Cell Lymphoma

Interventions: Biological: CD7-specific CAR gene-engineered T cells

First Posted Date: 2019-07-26

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT04033302

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

CAR-T Immunotherapy Targeting CD19- ALL

Phase 1

Conditions: B-cell Leukemia

Interventions: Biological: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR

First Posted Date: 2019-07-11

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04016129

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Zhongxi Children Hospital, Shijiazhuang, Hebei, China

Multiple CAR-T Cell Therapy Targeting AML

Phase 1

Conditions: Acute Myeloid Leukemia

Interventions: Biological: CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells

First Posted Date: 2019-07-08

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT04010877

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Lentiviral FIX Gene Therapy

Phase 1

Conditions: Hemophilia B

Interventions: Biological: YUVA-GT-F901

First Posted Date: 2019-05-23

Last Posted Date: 2019-05-23

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03961243

Immune Modulatory DC Vaccine Against Brain Tumor

Phase 1

Conditions: Diffuse Intrinsic Pontine Glioma or Glioblastoma

Interventions: Biological: Immunomodulatory DC vaccine to target DIPG and GBM

First Posted Date: 2019-04-16

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03914768

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China

IT and IV Lentiviral Gene Therapy for X-ALD

Not Applicable

Recruiting

Conditions: X-linked Adrenoleukodystrophy

Interventions: Genetic: Intracerebral LV gene therapy

First Posted Date: 2018-11-01

Last Posted Date: 2024-12-31

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT03727555

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Direct Lentiviral Injection Gene Therapy for MLD

Not Applicable

Recruiting

Conditions: Metachromatic Leukodystrophy (MLD)

Interventions: Biological: Lentivirus-mediated delivery of ARSA to the CNS.

First Posted Date: 2018-10-31

Last Posted Date: 2025-06-26

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03725670

Locations: 🇨🇳
Lung-Ji Chang, Shenzhen, Guangdong, China

Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)

Not Applicable

Recruiting

Conditions: Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

Interventions: Genetic: Direct intravenous injection of ivlv-ADA lentiviral vector

First Posted Date: 2018-08-24

Last Posted Date: 2024-07-17

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03645460

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Guilin Hospital of Chinese Traditional and Western Medicine, Guilin, Guangxi, China

Lentiviral Gene Therapy for CGD

Not Applicable

Conditions: Chronic Granulomatous Disease

Interventions: Genetic: Infusion of lentiviral TYF-CGD-modified autologous stem cells

First Posted Date: 2018-08-24

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 10

Registration Number: NCT03645486

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Immunotherapy Treating GI Cancer

Phase 1

Conditions: Cancer

Interventions: Biological: engineered immune cells

First Posted Date: 2018-08-03

Last Posted Date: 2018-08-03

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT03614650

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy